Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Overview of attention for article published in Investigational New Drugs, June 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#16 of 1,266)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 5 news outlets
policy: 1 policy source

patent: 3 patents

Citations

dimensions_citation: 451 Dimensions

Readers on

mendeley: 255 Mendeley

Summary News Policy documents Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 15 Oct 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.